NO20053125D0 - Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere. - Google Patents
Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.Info
- Publication number
- NO20053125D0 NO20053125D0 NO20053125A NO20053125A NO20053125D0 NO 20053125 D0 NO20053125 D0 NO 20053125D0 NO 20053125 A NO20053125 A NO 20053125A NO 20053125 A NO20053125 A NO 20053125A NO 20053125 D0 NO20053125 D0 NO 20053125D0
- Authority
- NO
- Norway
- Prior art keywords
- smallpox
- recombinant
- seq
- ati
- virus
- Prior art date
Links
- 241000700647 Variola virus Species 0.000 title 2
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000003740 cowpox Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201814 | 2002-11-25 | ||
| PCT/EP2003/012610 WO2004048582A2 (en) | 2002-11-25 | 2003-11-12 | Recombinant poxvirus comprising at least two cowpox ati promoters |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053125L NO20053125L (no) | 2005-06-24 |
| NO20053125D0 true NO20053125D0 (no) | 2005-06-24 |
Family
ID=32337938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053125A NO20053125D0 (no) | 2002-11-25 | 2005-06-24 | Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7300658B2 (de) |
| EP (1) | EP1567653B1 (de) |
| JP (1) | JP2006515170A (de) |
| KR (1) | KR20050083839A (de) |
| CN (1) | CN1717488A (de) |
| AT (1) | ATE365220T1 (de) |
| AU (1) | AU2003293675B2 (de) |
| CA (1) | CA2501168A1 (de) |
| CY (1) | CY1106883T1 (de) |
| DE (1) | DE60314541T2 (de) |
| DK (1) | DK1567653T3 (de) |
| EA (1) | EA012723B1 (de) |
| ES (1) | ES2288634T3 (de) |
| IL (1) | IL167844A (de) |
| MX (1) | MXPA05005549A (de) |
| NO (1) | NO20053125D0 (de) |
| NZ (1) | NZ540156A (de) |
| PL (1) | PL375740A1 (de) |
| PT (1) | PT1567653E (de) |
| UA (1) | UA85379C2 (de) |
| WO (1) | WO2004048582A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002231639B2 (en) * | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| IL164172A0 (en) * | 2002-05-16 | 2005-12-18 | Bavarian Nordic As | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| WO2009152969A1 (en) * | 2008-06-20 | 2009-12-23 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
| ES2618103T3 (es) * | 2008-11-21 | 2017-06-20 | Bavarian Nordic A/S | Vector que comprende múltiples secuencias de nucleótidos homólogas |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| US9567331B2 (en) | 2011-11-15 | 2017-02-14 | Trustees Of Boston University | Pyridopyrimidinone inhibitors of viruses |
| WO2016115116A1 (en) | 2015-01-12 | 2016-07-21 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2017089307A1 (en) * | 2015-11-24 | 2017-06-01 | Glaxosmithkline Intellectual Property Development Limited | Transient transfection method for retroviral production |
| WO2017089308A1 (en) * | 2015-11-24 | 2017-06-01 | Glaxosmithkline Intellectual Property Development Limited | Stable cell lines for retroviral production |
| PL3402802T3 (pl) | 2016-01-08 | 2023-06-05 | Geovax, Inc. | Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym |
| US20190030157A1 (en) | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
| JP7023929B2 (ja) * | 2016-08-09 | 2022-02-22 | シティ・オブ・ホープ | キメラポックスウイルス組成物及びその使用 |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443964A (en) * | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6869793B2 (en) * | 1996-09-24 | 2005-03-22 | Bavarian Nordic Research Institute | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| JP5639736B2 (ja) * | 1999-05-28 | 2014-12-10 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） | ポックスウイルスゲノムへの異種遺伝子の組込みのためのベクター |
| ATE373721T1 (de) | 2000-08-29 | 2007-10-15 | Wyeth Corp | Verpackung von replikon-partikeln eines positiv- strängigen rna-virus |
-
2003
- 2003-11-12 EA EA200500879A patent/EA012723B1/ru not_active IP Right Cessation
- 2003-11-12 PT PT03789029T patent/PT1567653E/pt unknown
- 2003-11-12 US US10/535,371 patent/US7300658B2/en not_active Expired - Fee Related
- 2003-11-12 CN CNA2003801040985A patent/CN1717488A/zh active Pending
- 2003-11-12 PL PL03375740A patent/PL375740A1/xx not_active Application Discontinuation
- 2003-11-12 NZ NZ540156A patent/NZ540156A/en not_active IP Right Cessation
- 2003-11-12 WO PCT/EP2003/012610 patent/WO2004048582A2/en not_active Ceased
- 2003-11-12 KR KR1020057007295A patent/KR20050083839A/ko not_active Abandoned
- 2003-11-12 ES ES03789029T patent/ES2288634T3/es not_active Expired - Lifetime
- 2003-11-12 AT AT03789029T patent/ATE365220T1/de active
- 2003-11-12 EP EP03789029A patent/EP1567653B1/de not_active Expired - Lifetime
- 2003-11-12 MX MXPA05005549A patent/MXPA05005549A/es active IP Right Grant
- 2003-11-12 UA UAA200506292A patent/UA85379C2/ru unknown
- 2003-11-12 DK DK03789029T patent/DK1567653T3/da active
- 2003-11-12 JP JP2004554335A patent/JP2006515170A/ja active Pending
- 2003-11-12 DE DE60314541T patent/DE60314541T2/de not_active Expired - Lifetime
- 2003-11-12 CA CA002501168A patent/CA2501168A1/en not_active Abandoned
- 2003-11-12 AU AU2003293675A patent/AU2003293675B2/en not_active Ceased
-
2005
- 2005-04-04 IL IL167844A patent/IL167844A/en not_active IP Right Cessation
- 2005-06-24 NO NO20053125A patent/NO20053125D0/no not_active Application Discontinuation
-
2007
- 2007-09-20 CY CY20071101220T patent/CY1106883T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1567653T3 (da) | 2007-10-15 |
| NO20053125L (no) | 2005-06-24 |
| AU2003293675B2 (en) | 2009-04-23 |
| WO2004048582A2 (en) | 2004-06-10 |
| WO2004048582A3 (en) | 2004-08-12 |
| MXPA05005549A (es) | 2005-08-16 |
| EP1567653B1 (de) | 2007-06-20 |
| UA85379C2 (ru) | 2009-01-26 |
| EP1567653A2 (de) | 2005-08-31 |
| CY1106883T1 (el) | 2012-09-26 |
| DE60314541T2 (de) | 2008-02-28 |
| NZ540156A (en) | 2006-11-30 |
| PT1567653E (pt) | 2007-10-01 |
| CN1717488A (zh) | 2006-01-04 |
| PL375740A1 (en) | 2005-12-12 |
| US20060153874A1 (en) | 2006-07-13 |
| IL167844A (en) | 2011-03-31 |
| KR20050083839A (ko) | 2005-08-26 |
| CA2501168A1 (en) | 2004-06-10 |
| ES2288634T3 (es) | 2008-01-16 |
| EA012723B1 (ru) | 2009-12-30 |
| US7300658B2 (en) | 2007-11-27 |
| DE60314541D1 (de) | 2007-08-02 |
| EA200500879A1 (ru) | 2005-10-27 |
| JP2006515170A (ja) | 2006-05-25 |
| AU2003293675A1 (en) | 2004-06-18 |
| ATE365220T1 (de) | 2007-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106883T1 (el) | Ανασυνδυασμενος ιος ευλογιας που περιεχει τουλαχιστον δυο υποκινητες ατι ιου ευλογιας αγελαδας. | |
| UA82998C2 (ru) | Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті | |
| ES2800623T3 (es) | Promotor PR13.5 para respuestas contundentes de células T y anticuerpos | |
| RU98101904A (ru) | Рекомбинантный вирус mva и его использование | |
| US6869793B2 (en) | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines | |
| IL204539A (en) | Foxvirus virus containing defective genes and a losing gene | |
| KR20040108798A (ko) | 변형 백시니아 바이러스 안카라(ｍｖａ)의 게놈내삽입부위로서의 유전자내 영역 | |
| US11286500B2 (en) | Recombinant Orf virus vector | |
| MXPA02011545A (es) | Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| JP5952112B2 (ja) | ポックスウイルスまたは他の感染性因子に対する免疫の急速な誘導に改変ポックスウイルスを使用する方法 | |
| AU2002337083A1 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
| IL164179A0 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
| JPWO2021154828A5 (de) | ||
| CA2430115A1 (en) | Recombinant rsv virus expression systems and vaccines | |
| DE60117053D1 (de) | Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten | |
| CN101142319B (zh) | 基于使用修饰安卡拉痘苗病毒的疫苗 | |
| NZ512341A (en) | Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments | |
| JP2009232836A5 (de) | ||
| BR0316553A (pt) | Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina | |
| WO2024259078A3 (en) | Anti-tick vaccines and methods of use thereof | |
| DK200201813A (da) | Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |